| Product Name | Anlotinib Dihydrochloride (AL3818 Dihydrochloride); Anlotinib 2HCl |
|---|---|
| CAS | 1360460-82-7 |
| Formula | C23H24Cl2FN3O3 |
| MW | 480.36 |
| Appearance | Light yellow to yellow powder |
| Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
|---|---|---|---|---|
| 1 mg | 3-5days | ¥500.00 | Visible after login | |
| 5 mg | 3-5days | ¥1450.00 | Visible after login | |
| 10 mg | 3-5days | ¥2500.00 | Visible after login |
| Product Name | Anlotinib Dihydrochloride (AL3818 Dihydrochloride); Anlotinib 2HCl |
|---|---|
| CAS | 1360460-82-7 |
| Formula | C23H24Cl2FN3O3 |
| MW | 480.36 |
| Appearance | Light yellow to yellow powder |
Anlotinib, also known as AL3818 and Catequentinib, is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.